Ancient Immune Protein C3 Enhances Cancer Immunotherapy Efficacy in Tumors
Researchers at Nagoya University in Japan have discovered that the ancient immune protein C3, when produced within tumors, can significantly enhance the effectiveness of cancer immunotherapy. The study, published in Nature Communications, reveals that C3 prevents the accumulation of immunosuppressive myeloid cells in the tumor microenvironment, thereby allowing the immune system to better attack cancer cells. This effect is specific to C3 produced locally within the tumor, as opposed to C3 circulating in the bloodstream, which does not influence treatment outcomes. The research involved experiments on mice, demonstrating that reducing C3 production by fibroblasts within tumors decreased the efficacy of immunotherapy, while circulating C3 levels had minimal impact. The findings suggest that artificially boosting local C3 production could improve treatment responses in tumors that naturally produce insufficient amounts of this protein. 
